WHO Recommends Remdesivir for Severe COVID-19: Expert Perspective on Updated Therapeutic Guideline

The World Health Organization (WHO) recently updated its Therapeutics and COVID-19: living guideline to include the conditional recommendation for the use of remdesivir (Veklury^®; Gilead Sciences) in patients with severe COVID-19 and the conditional recommendation against its use in those with critical COVID-19. Previously, the WHO conditionally recommended remdesivir for patients with non-severe COVID-19.

Patient Care Online sat down with Elizabeth Sapey, BSc, MBBS, PhD, professor of Acute and Respiratory Medicine at the Institute of Inflammation and Ageing at the University of Birmingham, to further discuss the WHO’s therapeutic guideline update. In the video below, Dr Sapey discusses the updated recommendations and findings from the randomized, double-blind, placebo-controlled PINETREE study that were the "linchpin" for the change in recommendation.